Lepodisiran 13 items
Trials, agents, guidance
- Agent Lepodisiran (LY3819469)
- Trial ACCLAIM-Lp(a)
- Trial ALPACA (lepodisiran phase 2)
Studies
- ALPACA: lepodisiran 400 mg lowers Lp(a) by 94 percent from day 60 to 180, and by 95 percent over a year with a second dose (Nissen et al., NEJM 2025)
- Lepodisiran phase 1: a single 608 mg dose keeps Lp(a) 94 percent down at day 337 (Nissen et al., JAMA 2023)
- Five late-stage RNA and small-molecule Lp(a) therapies near approval, from pelacarsen to muvalaplin (Curr Atheroscler Rep 2026)
- Lepodisiran advances to phase 3 ACCLAIM-Lp(a) outcomes trial, updated review (Cardiol Rev 2026)
- Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease
- Molecular Mechanisms and Therapeutic Targets of RNA-Based and Traditional Lipid-Lowering Agents in Residual Cardiovascular Risk: A Scoping Review of Key Directions Towards Future Perspectives
Video and podcasts
